Takeda’s Zika vaccine candidate wins FDA fast-track status

Takeda’s Zika vaccine candidate, TAK-426, received FDA fast-track designation. (Image: Health.mil)

For years, experts have expressed worries about the reactive nature of emerging disease vaccine development, most recently with the Zika outbreak. But even after the WHO stopped classifying Zika as an "emergency" in late 2016, Takeda pressed ahead with its program, this week winning the FDA's fast-track designation.

FDA granted the designation to TAK-426, a purified, inactivated, alum-adjuvanted vaccine with whole Zika virus. Last November, Takeda advanced the candidate into a 240-subject phase 1 study in the continental U.S. and Puerto Rico.

From the FDA's perspective, granting the fast-track label means the agency deems Zika a serious condition with an unmet medical need. There are no approved vaccines or drugs against the infection, which can cause microcephaly and other congenital brain abnormalities in infants born to infected mothers


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

RELATED: Takeda pushes U.S.-backed Zika vaccine into the clinic

For Takeda, the designation means more frequent interactions with the agency and eligibility for accelerated approval and a priority review.

“We recognize the public health threat posed by the Zika virus,” Laurence De Moerlooze, Ph.D., Takeda’s global Zika program lead, said in a statement on Monday. She said the Japanese pharma prioritized development of the candidate after the Biomedical Advanced Research and Development Authority (BARDA) committed $19.8 million to cover development costs through phase 1 and promised up to $312 million in assistance through a potential FDA approval.

The Zika virus has significantly died down after an outbreak caught the world off guard in late 2015 and through 2016. Symptomatic cases reported to the CDC from U.S. states and territories were 418 and 637, respectively in 2017, compared to 5,102 and 36,079 for 2016, according to the most recent agency data.

RELATED: Regret it or not, the Zika vaccine Sanofi walked away from shows early promise

Back in November 2016, the WHO changed its classification for Zika from a “public health emergency " to a “long-term commitment." Some experts voiced their concern that the decision would dampen enthusiasm for vaccine development, and as a consequence, a lack of preparedness if the disease spreads again. Some have also warned of the reactive nature of vaccine R&D could shift developers’ attention every time a new outbreak emerges, drawing comparisons with how Zika replaced Ebola on the international community’s agenda.

Although the waning epidemic means fewer people are falling ill, the decrease in cases also makes it tougher to conduct late-phase clinical studies to prove vaccine efficacy. Sanofi cited that as one of the reasons behind its decision to drop out of an agreement to license a Zika vaccine candidate developed by the U.S. Army.

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.